Salvatore Mascia

Salvatore Mascia

Auto-generated profile, based on publicly available information

Salvatore Mascia

CONTINUUS Pharmaceuticals, Woburn, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
CHChuntian Hu
Chuntian Hu
CTChristopher J. Testa
Christopher J. Testa
WWWei Wu
Wei Wu
KSKhrystyna Shvedova
Khrystyna Shvedova
DSDongying Erin Shen
Dongying Erin Shen
SMSalvatore Mascia
Salvatore Mascia
We report here a fully automated, end-to-end, integrated continuous manufacturing process for a small-molecule generic medication with built-in quality assurance. The entire process fits into a box of 30.7 m2 modular footprint and a total residence time of less than 30 h, with a throughput up to 40.3 × 106 tablets per year.

11 June 2020 in Green Chemistry
Verified
Journal Article
Closed access
PDF file
CHChuntian Hu
Chuntian Hu
CTChristopher J. Testa
Christopher J. Testa
SBStephen C. Born
Stephen C. Born
WWWei Wu
Wei Wu
KSKhrystyna Shvedova
Khrystyna Shvedova
SMSalvatore Mascia
Salvatore Mascia
Much less waste was generated by the end-to-end Integrated Continuous Manufacturing (ICM) process compared to the batch process.

21 August 2020 in Reaction Chemistry & Engineering
Verified
Journal Article
Closed access
PDF file
CHChuntian Hu
Chuntian Hu
BSBrianna T. Shores
Brianna T. Shores
RDRachel A. Derech
Rachel A. Derech
CTChristopher J. Testa
Christopher J. Testa
PHPaul Hermant
Paul Hermant
SMSalvatore Mascia
Salvatore Mascia
The influence of PFR on crystal size distribution, reaction and crystallization yields, and supersaturation level was investigated.

11 July 2019 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
CHChuntian Hu
Chuntian Hu
CTChristopher J. Testa
Christopher J. Testa
BSBrianna T. Shores
Brianna T. Shores
WWWei Wu
Wei Wu
KSKhrystyna Shvedova
Khrystyna Shvedova
SMSalvatore Mascia
Salvatore Mascia
Forms I–III and dihydrate carbamazepine (CBZ) were prepared and confirmed by X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC). Influences of supersaturation (σ), stirring, anti-solvent (H2O), and polymer type on the resultant polymorph are discussed. For a CBZ ethanol solution at 5 °C, more than 10 h was required to form crystals when σ was 0.5, while less than 2 s was required when σ was increased to 9.0. Very fine needle-shaped Form II crystals were obtained when σ ≥ 7.5. Higher stirring rates facilitated the formation of Form III CBZ. Continuous heterogeneous crystallization of Form III on polyvinyl alcohol (PVA, MW 89 000–98 000) was achieved in a one-stage mixed suspension mixed product removal (MSMPR) crystallizer at 15 °C and 300 rpm. At 5 °C and 40 rpm, only Form II crystals were obtained. However, Form II CBZ gradually transformed to Form III within 2 residence times, and the transition process was irreversible.

12 June 2020 in Organic Process Research & Development
Verified
Journal Article
Closed access
BSBrianna T. Shores
Brianna T. Shores
PSPeter E. Sieg
Peter E. Sieg
ANAna T. Nicosia
Ana T. Nicosia
CHChuntian Hu
Chuntian Hu
SBStephen C. Born
Stephen C. Born
SMSalvatore Mascia
Salvatore Mascia

28 August 2018 in Organic Process Research & Development
Verified
Journal Article
Closed access
WWWei Wu
Wei Wu
MLMatthew G. Lesher
Matthew G. Lesher
CHChuntian Hu
Chuntian Hu
KSKhrystyna Shvedova
Khrystyna Shvedova
BTBayan Takizawa
Bayan Takizawa
SMSalvatore Mascia
Salvatore Mascia